Guest: Dr. Melissa Price, VP of Clinical and Regulatory Affairs, Heat Biologics, Inc., Durham
Topics: Cancer immunotherapy, Heat Biologics, a clinical-stage company with two drug candidates in clinical trials, allogeneic versus autologous immunotherapy, Heat’s ImPACT platform (Immune Pan-Antigen Cytotoxic Therapy)
Cancer Immunotherapy: SCIENCE magazine’s Breakthrough of the Year, 2013